Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Stage I Randomized Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers

Not Applicable

Completed

Conditions: Child Abuse and Neglect
Maternal Substance Use

Interventions: Behavioral: Mentalizing Therapy for Substance Using Mothers
Behavioral: Standard Parent Education for Substance Using Mothers

First Posted Date: 2006-04-27

Last Posted Date: 2020-04-09

Lead Sponsor: Yale University

Target Recruit Count: 47

Registration Number: NCT00319436

Locations: 🇺🇸
The APT Foundation, New Haven, Connecticut, United States

Buprenorphine and Integrated HIV Care

Phase 4

Completed

Conditions: AIDS
HIV Infections
Drug Addiction
Substance-related Disorders
Human Immunodeficiency Virus

Interventions: Behavioral: Counseling
Other: Physician Management

First Posted Date: 2006-04-24

Last Posted Date: 2020-04-03

Lead Sponsor: Yale University

Target Recruit Count: 52

Registration Number: NCT00317460

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Specialized Treatment Early in Psychosis (STEP)

Not Applicable

Completed

Conditions: Schizophrenia and Disorders With Psychotic Features

Interventions: Behavioral: Cognitive Behavioral Group Therapy
Other: Treatment as Usual in the community
Behavioral: Cognitive remediation
Drug: Medications
Behavioral: MFG
Behavioral: Assertive case management

First Posted Date: 2006-03-31

Last Posted Date: 2017-02-08

Lead Sponsor: Yale University

Target Recruit Count: 120

Registration Number: NCT00309452

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

Transcranial Magnetic Stimulation for "Voices"

Phase 2

Completed

Conditions: Hallucinations
Schizophrenia

Interventions: Device: Active 1-Hertz Repetitive transcranial magnetic stimulation
Device: 1-hertz Repetitive Transcranial Magnetic Stimulation

First Posted Date: 2006-03-30

Last Posted Date: 2020-04-02

Lead Sponsor: Yale University

Target Recruit Count: 85

Registration Number: NCT00308997

Locations: 🇺🇸
Yale Psychiatric Research, New Haven, Connecticut, United States

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 1

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: docetaxel
Other: placebo
Drug: idronoxil

First Posted Date: 2006-03-17

Last Posted Date: 2018-01-17

Lead Sponsor: Yale University

Target Recruit Count: 31

Registration Number: NCT00303888

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Tele-HF: Yale Heart Failure Telemonitoring Study

Not Applicable

Completed

Conditions: Congestive Heart Failure

Interventions: Other: Telemonitoring

First Posted Date: 2006-03-15

Last Posted Date: 2020-03-30

Lead Sponsor: Yale University

Target Recruit Count: 1660

Registration Number: NCT00303212

Locations: 🇺🇸
Morehouse School of Medicine/Cardiology, Atlanta, Georgia, United States
🇺🇸
Heart Clinic of Louisiana, Marrero, Louisiana, United States
🇺🇸
Cardiology Specialists, Ltd., Westerly, Rhode Island, United States

and more 30 locations

Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Not Applicable

Completed

Conditions: Liver Cancer

Interventions: Device: Drug-eluting beads loaded with doxorubicin hydrochloride

First Posted Date: 2006-02-17

Last Posted Date: 2018-07-18

Lead Sponsor: Yale University

Target Recruit Count: 20

Registration Number: NCT00293397

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Enhancing the Prospective Prediction of Psychosis

Completed

Conditions: Schizophrenia
Psychotic Disorders

First Posted Date: 2006-02-13

Last Posted Date: 2014-06-10

Lead Sponsor: Yale University

Target Recruit Count: 268

Registration Number: NCT00291200

Locations: 🇺🇸
Prevention through Risk Identification Management and Education (PRIME) Clinic, New Haven, Connecticut, United States
🇨🇦
PRIME Clinic, Toronto, Ontario, Canada

Levetiracetam Treatment of Tardive Dyskinesia

Phase 3

Completed

Conditions: Tardive Dyskinesia

Interventions: Drug: levetiracetam
Drug: placebo

First Posted Date: 2006-02-13

Last Posted Date: 2014-06-06

Lead Sponsor: Yale University

Target Recruit Count: 50

Registration Number: NCT00291213

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

Glycine vs Placebo for the Schizophrenia Prodrome

Phase 2

Completed

Conditions: Schizophrenia Prodrome

Interventions: Drug: Placebo
Drug: Glycine

First Posted Date: 2006-02-13

Last Posted Date: 2020-04-02

Lead Sponsor: Yale University

Target Recruit Count: 8

Registration Number: NCT00291226

Locations: 🇺🇸
PRIME Clinic, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy